<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04797910</url>
  </required_header>
  <id_info>
    <org_study_id>NFEC-2021-002</org_study_id>
    <nct_id>NCT04797910</nct_id>
  </id_info>
  <brief_title>Effect of Antiviral Therapy on HVPG in Patients With Viral Cirrhosis</brief_title>
  <official_title>Effect of Antiviral Therapy on HVPG in Patients With Viral Cirrhosis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Nanfang Hospital of Southern Medical University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Nanfang Hospital of Southern Medical University</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Complications associated with portal hypertension are the leading cause of death in patients&#xD;
      with cirrhosis. Until now, hepatic venous pressure gradient (HVPG) - the difference between&#xD;
      the wedged hepatic venous pressure (WHVP) and the free hepatic vein pressure (FHVP)- has been&#xD;
      the criterion standard to determine portal pressure. Antiviral therapy may decrease HVPG&#xD;
      which needs to be verified.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">March 10, 2021</start_date>
  <completion_date type="Anticipated">December 31, 2022</completion_date>
  <primary_completion_date type="Anticipated">December 31, 2021</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>HVPG changed and reached the response standard</measure>
    <time_frame>one year</time_frame>
    <description>HVPG response to therapy indicates a decrease in HVPG of at least 10% from baseline or to less than 12 mmHg after chronic treatment with NSBBs.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Antiviral therapy achieved a virological response</measure>
    <time_frame>one year</time_frame>
    <description>HBV-DNA remained undetectable for successive two times.</description>
  </secondary_outcome>
  <enrollment type="Anticipated">24</enrollment>
  <condition>Portal Hypertension</condition>
  <eligibility>
    <study_pop>
      <textblock>
        Patients with hepatitis B cirrhosis&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Patients with viral cirrhosis were diagnosed;&#xD;
&#xD;
          -  Age 18-80 years;&#xD;
&#xD;
          -  Need and willing to accept measure HVPG;&#xD;
&#xD;
          -  First HVPG measurement of more than 5 mmHg;&#xD;
&#xD;
          -  Signed Informed Consent&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Patients with viral cirrhosis have been treated with antiviral therapy and have&#xD;
             achieved virological response;&#xD;
&#xD;
          -  Ready to accept or have accepted a TIPS procedure;&#xD;
&#xD;
          -  Splenic embolization was performed;&#xD;
&#xD;
          -  Inaccurate measurement of HVPG due to combined hepatic venous shunt;&#xD;
&#xD;
          -  Complicated with alcoholic liver disease, autoimmune liver disease or other types of&#xD;
             liver disease;&#xD;
&#xD;
          -  Complicated with liver cancer or other organ malignancy;&#xD;
&#xD;
          -  Combined with severe cardiopulmonary disease affects survival;&#xD;
&#xD;
          -  Complicated with severe renal insufficiency;&#xD;
&#xD;
          -  Concomitant portal vein cavernous degeneration or extensive portal vein thrombosis;&#xD;
&#xD;
          -  Women who are planning to become pregnant or who are pregnant or breastfeeding.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Xiaofeng Zhang</last_name>
    <phone>+86-18565552050</phone>
    <email>1282614092@qq.com</email>
  </overall_contact>
  <verification_date>March 2021</verification_date>
  <study_first_submitted>March 7, 2021</study_first_submitted>
  <study_first_submitted_qc>March 11, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">March 15, 2021</study_first_posted>
  <last_update_submitted>March 11, 2021</last_update_submitted>
  <last_update_submitted_qc>March 11, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">March 15, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hypertension, Portal</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

